Evidence map›Paper›PMID 29550766›Full record

Trial reportAnnals of the rheumatic diseases2018

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.

Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser and 3 more

2 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of the rheumatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 164 papers, 25 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 25 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02404350 phase3completednot on this map

A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5)

TypeinterventionalSponsorNovartis PharmaceuticalsRan2015 to 2019Enrolled997ConditionsPsoriatic ArthritisArmsSecukinumab
NCT06730334 recruitingnot on this mapstarted 2023, after this paper: background citation

A Single Centre Prospective Cohort Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS)

TypeobservationalSponsorNanjing Medical UniversityRan2023 to 2028Enrolled400ConditionsPsoriatic Arthritis, Secukinumab, Ultrasonography
3 · Its place in the literature

Who cites it

164 citing papers in PubMed, 25 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2021
    Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

104 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Philip MeaseDepartment of Rheumatology, Swedish Medical Center and University of Washington, Seattle, Washington, USA.ORCID 0000-0002-6620-0457
Désirée van der HeijdeDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Robert LandewéDepartment of Clinical Rheumatology and Immunology, University of Amsterdam and Atrium Medical Center, Amsterdam, The Netherlands.
Shephard MpofuNovartis Pharma AG, Basel, Switzerland.
Proton RahmanFaculty of Medicine, Memorial University, St. Johns, Newfoundland, Canada.
Hasan TahirWhipps Cross University Hospital, London, UK.
Atul SinghalSouthwest Rheumatology, Dallas, Texas, USA.
Elke BoettcherRheumazentrum Favoriten, Vienna, Austria.
Sandra NavarraSection of Rheumatology, University of Santo Tomas Hospital, Manila, Philippines.
Karin MeiserNovartis Pharma AG, Basel, Switzerland.
Aimee ReadieNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Luminita PricopNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Ken AbramsNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the effect of subcutaneous (s.c.) secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic progression in patients with psoriatic arthritis (PsA).

methodsAdults (n=996) with active PsA were randomised 2:2:2:3 to s.c. secukinumab 300 mg or 150 mg with loading dose (LD), 150 mg without LD or placebo. All groups received secukinumab or placebo at baseline, weeks 1, 2 and 3 and then every 4 weeks from week 4. The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response at week 16.

resultsSignificantly more patients achieved an ACR20 response at week 16 with secukinumab 300 mg with LD (62.6%), 150 mg with LD (55.5%) or 150 mg without LD (59.5%) than placebo (27.4%) (p<0.0001 for all; non-responder imputation). Radiographic progression, as measured by van der Heijde-modified total Sharp score, was significantly inhibited at week 24 in all secukinumab arms versus placebo (p

conclusionS.c. secukinumab 300 mg and 150 mg with and without LD significantly improved clinical signs and symptoms and inhibited radiographic structural progression versus placebo at week 24 in patients with PsA. TRIAL REGISTRATION NUMBER: NCT02404350; Results.

Indexed as

AdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, PsoriaticDisease ProgressionDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansInjections, SubcutaneousInterleukin-17MaleMiddle AgedRadiographySeverity of Illness IndexAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentsInterleukin-17secukinumabcytokinesdmards (biologic)psoriatic arthritistreatment

Identifiers

PMID29550766
PMCPMC5965348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.